Dostarlimab is a humanized anti–PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeutic function of the antibody and reduce drug efficacy. Therefore, programs developing therapeutic biologics need to develop and validate assays that adequately assess the presence of NAbs in the serum of patients treated with biologic therapies. Presented here is the development and validation of a competitive ligand-binding assay that specifically detects anti-dostarlimab NAbs in human serum. Precision, sensitivity, hook effect, selectivity, assay robustness, stabilities, and system suitability were evaluated. In addition, drug tolerance of the assay with the implementation of a drug removal process was investigated. The cut point factor for the detection of NAbs in human serum at a 1% false-positive rate was determined. The assay’s precision, sensitivity, hook effect, selectivity, robustness, and drug interference were tested and found to be acceptable. With system suitability and stability established, this assay has been used to evaluate NAbs to guide the development of dostarlimab.
Trial registration: Clinicaltrials.gov, NCT02715284. Registered 9 March 2016
Immunotherapy with antibodies directed at the programmed death 1 (PD-1)/PD ligand 1(PD-L1) axis has shown remarkable activity in a variety of tumor types in clinical trials and has been approved worldwide for a number of malignancies (Robert et al. 2014; Weber et al. 2015; Fehrenbacher et al. 2016; Antonia et al. 2017; Apolo et al. 2017; Seiwert et al. 2016; Ansell et al. 2015; El-Khoueiry et al. 2017; Kaufman et al. 2016; Gong et al. 2018; Ahn et al. 2019; Khozin et al. 2019). Dostarlimab (JEMPERLI; TSR-042) is a humanized anti–PD-1 monoclonal antibody (mAb) (Oaknin et al. 2018). In the USA, dostarlimab was recently approved as a monotherapy in adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or after a platinum-containing regimen or dMMR recurrent or advanced solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options (US Food and Drug Administration 2021a; US Food and Drug Administration 2021b; Andre et al. 2021; ClinicalTrials.gov 2016). In the EU, dostarlimab was recently approved as a monotherapy in adult patients with recurrent or advanced dMMR/microsatellite instability–high endometrial cancer that has progressed on or after treatment with a platinum-containing regimen (Oaknin et al. 2018; Andre et al. 2021; ClinicalTrials.gov 2016; European Medicines Agency 2021). As with other immunotherapeutic agents, anti-drug antibodies (ADAs) may emerge and be detectable after administration of dostarlimab (Pineda et al. 2016). However, dostarlimab is a humanized mAb, and as such, has a lower risk of eliciting ADAs or neutralizing (NAbs) than non-humanized mAbs (Davda et al. 2019).
However, the production of ADAs is generally a treatment risk with therapeutic antibodies and can lead to an altered pharmacokinetic (PK) profile, which in turn may impact the safety and efficacy of therapeutic antibodies (Garcês and Demengeot 2018; Bloem et al. 2017). ADAs can be (1) binding, leading to minimal or no impact; (2) clearing, leading to impact through an altered PK profile; (3) sustaining, leading to a prolonged exposure that may change the efficacy and/or safety; or (4) neutralizing, leading to reduced pharmacological activity of the therapeutic antibody (Garcês and Demengeot 2018; Bloem et al. 2017).
Thus, the presence of NAbs is concerning because they block the therapeutic function of the antibody and are likely to lead to reduced efficacy (Garcês and Demengeot 2018; Bloem et al. 2017; Gunn et al. 2016). Furthermore, NAbs may lead to safety issues, such as hypersensitivity and anaphylaxis Gunn et al. 2016; Krishna and Nadler 2016). Therefore, programs developing therapeutic antibodies need to develop and validate assays that adequately assess the presence of NAbs in the serum of patients treated with such therapeutic agents.
Cell-based reporter assays have been developed and validated for detecting NAbs, including a cell-based bioluminescent reporter assay that quantifies therapeutic mAbs against PD-1 and PD-L1 (Liao et al. 2012; Cong et al. 2015; Jolicoeur and Tacey 2012).
Regulatory agencies prefer cell-based assays because they rely on cellular responses to NAb-mediated inhibition of therapeutic antibodies (Wu et al. 2016). Because of their mode of detection, these assays have been considered more biologically relevant than non–cell-based assays (Bloem et al. 2017; Liao et al. 2012; Cong et al. 2015; Jolicoeur and Tacey 2012). However, cell-based assays are labor intensive and highly variable and exhibit low serum tolerance and poor drug tolerance (Bloem et al. 2017; Liao et al. 2012; Cong et al. 2015; Jolicoeur and Tacey 2012; Wu et al. 2016). In contrast to cell-based assays, non–cell-based assays often rely on binding of the drug and target for signal detection and quantitation. Competitive ligand-binding assays, used to characterize NAbs, have been shown to provide higher sensitivity, a wider dynamic range, increased precision, and better matrix tolerance than cell-based assays (Wu et al. 2018). Although regulatory agencies generally prefer cell-based assays, the United States Food and Drug Administration and the European Medicines Agency recognize both cell-based and non–cell-based competitive ligand-binding assays as valid measurements of NAbs in some cases (Jolicoeur and Tacey 2012; Wu et al. 2016). The selection of either cell-based or non–cell-based assays is driven by several different variables, including therapeutic mechanism of action (MOA), assay performance characteristics, and risk of immunogenicity, with therapeutic MOA being the primary determinant (Wu et al. 2016).
Here, we present the development and validation of a competitive ligand-binding assay that is specific for the detection of anti-dostarlimab NAbs in human serum. We validated the assay’s precision, sensitivity, hook effect, selectivity, robustness, stability, and system suitability. In addition, we investigated the drug tolerance of the assay with the implementation of a drug removal process, as well as the possibilities for false-negative results. The utility of this assay as it pertains to the dostarlimab clinical development program is also briefly discussed.
Materials and methods
Critical reagents for this assay were as follows: a mouse anti-dostarlimab mAb (Precision Antibodies, Columbia, MD) generated from clone #6G10 at a concentration of 1.15 mg/mL; dostarlimab (WuXi, Philadelphia, PA) at a concentration of 20.7 mg/mL; biotinylated human PD-1 (ACRO Biosystems, Newark, DE) at a concentration of 200 μg/mL; and SULFO-TAG–labeled human PD-L1 (CR0; Meso Scale Diagnostics [MSD], Rockville, MD) at a concentration of 2106 μg/mL.
Preparation of dostarlimab drug solution
The initial stock solution of dostarlimab was diluted in LowCross-Buffer (Boca Scientific, Westwood, MA) to a concentration of 1608 ng/mL, which is 6 times the desired final concentration (268 ng/mL). The prepared dostarlimab solution was aliquoted and stored at − 70 °C.
Preparation of assay control samples
The negative control (NC) was prepared by adding 250 μg/mL dostarlimab (GSK, Waltham, MA) into pooled normal human serum (pNHS; Bio IVT, Westbury, NY) and freezing the solution for 12 h. After thawing, dostarlimab was removed from the NC samples via the drug removal procedure (see below). The low-positive control (LPC) and high-positive control (HPC) were prepared by mixing dostarlimab and anti-dostarlimab NAb clone 6G10 in pNHS at 250 μg/mL and 500 ng/mL, respectively, for the LPC and at 250 μg/mL and 2000 ng/mL, respectively, for the HPC. The solution was then subjected to the same freeze–thaw–drug removal procedure as the NC. Once prepared, the NC, LPC, and HPC were stored at − 70 °C.
Drug removal procedure
Excess dostarlimab was removed from serum and control samples prior to performing the NAb detection assay. Biotinylated human PD-1 stock solution (200 μg/mL) was prepared by dissolving 200 μg of PD-1 in 1 mL of dH2O. Magnetic streptavidin Dynabeads (Thermo Fisher Scientific, Waltham, MA) were prepared by transferring 140 μL of streptavidin magnetic beads to a tube (approximately 50% of bead volume) where they were subsequently washed once using the magnetic stand with 0.5 mL of wash/bind buffer. To bind human PD-1 to the magnetic beads, 70 μL (14 μg) of biotinylated PD-1 protein was added to the washed beads, and the mixture was incubated for 1 hour at ambient temperature while shaking at 1000 rpm. The PD-1 solution was then removed from the beads using the magnetic stand, and the beads were washed 3 times using the magnetic stand with 0.5 mL wash/bind buffer.
The positive control (PC) was prepared by adding dostarlimab and NAb to pNHS to achieve a final concentration of 250 μg/mL of dostarlimab and the desired concentration of NAb in 70 μL of pNHS. Drug removal was accomplished by adding a one-tenth volume of 1 M acetic acid to serum or control solutions and incubating at ambient temperature for 2 h, resulting in a pH of 3.0 with no change of ADA affinity observed. A one-tenth volume of 1 M Tris base was added to neutralize the samples.
The sample solution was immediately added to the pre-washed PD-1–coated magnetic beads and incubated for 1 hour at ambient temperature while shaking at 1000 rpm. The samples were then separated from the streptavidin beads by magnetic separation and subsequently used in the NAb assay, or alternatively, stored at − 70 °C.
NAb detection assay
The streptavidin-coated Gold SECTOR plates (MSD) were blocked with 1% bovine serum albumin (Gemini Bio, West Sacramento, CA) in phosphate-buffered saline (PBS) for 1 hour at ambient temperature with shaking at 450 rpm and thoroughly washed (3 cycles on a plate washer with 0.05% Tween-20 in PBS). In a dilution plate, 20 μl of prepared dostarlimab solution (1608 ng/mL) was added to 60 μL of drug removal samples or controls, and the resulting solutions were incubated for 1 hour at ambient temperature with shaking at 450 rpm. A Master Mix solution of 12 nM biotinylated PD-1 and 12 nM SULFO-TAG–labeled human PD-L1 was prepared in Low Cross-Buffer. Then, 40 μL of Master Mix was added to each well of the dilution plate, which was incubated for 1 hour at ambient temperature with shaking at 450 rpm in the dark. The final drug concentration was 268 ng/mL, which was selected based on the following: the linearity range for dostarlimab drug concentration to ECL signal was found to be 0–300 ng/mL; the highest drug concentration in this range led to the lowest ECL signal in the test sample; and any ECL signal increase due to NAb interaction in the assay introduced a better signal to noise ratio. Therefore, approximately 90% of the 300 ng/mL (which was considered to be the high limit of quantification) was used to maintain the assay reproducibility. From each well of the dilution plate, 50 μL was transferred to the washed streptavidin-coated plate and incubated for 1 hour at ambient temperature in the dark. Following incubation, the wells were washed with Tween-20 PBS, as described above, then 100 μL of 2× Read Buffer (MSD) was added to each well. The plate was subsequently read on an MSD SECTOR Imager (MSD) to attain the electrochemiluminescence (ECL) signal.
Sixty individual human cancer serum samples were obtained from the disease population, were divided into 4 groups with 30, 30, 40, and 20 samples in groups A, B, C, and D, respectively. The plate for group D also included 11 sensitivity samples. Each group was tested twice by 2 analysts across 3 days. Each analyst tested at least 1 set of sensitivity samples. The reported value for each test sample was the mean ECL response from duplicate wells on a plate. The NCs were tested 4 times on each plate, and the means of the duplicate wells were reported for a total of 32 ECL values. The LPC and HPC samples were tested twice on each plate for a total of 16 mean ECL values for each PC.
Sources of variation
All statistical analyses were completed using JMP Pro version 12.1.0 (JMP; Cary, NC), and methods used were consistent with recommendations by Shankar et al. (2008). Statistical outliers were determined using a quartile range outlier method. The statistical outliers in the upper and lower quartiles were defined as Q3 + 1.5 × (Q3 − Q1) and Q1 − 1.5 × (Q3 − Q1), where Q3 is the 75th percentile and Q1 is the 25th percentile. Outliers identified by these criteria were removed, and the model was re-fit. Normality of residual values was evaluated by the Shapiro-Wilk test (Mire-Sluis et al. 2004). In addition, the skewness coefficient was calculated as a relative measure of symmetry (Shapiro and Wilk 1965).
If skewness coefficient was less than − 1 or greater than + 1, the distribution of the data was highly skewed; if skewness was between − 1 and − 1/2 or between + 1/2 and + 1, the distribution was moderately skewed; and if skewness was between − 1/2 and + 1/2, the distribution was approximately symmetric. The parametric cut point estimates are typically recommended if normality distribution is confirmed (if P > 0.05); however, if normality cannot be assumed, the parametric cut point estimate may be used if the data are not highly skewed (if skewness is between − 1 and + 1).
NAb assay cut point
Signal to noise (S/N) ratio values were obtained by dividing the ECL signal value from each individual serum sample by the mean of the NC ECL values from the corresponding plate. After exclusion of analytic outliers from the set of NC values, the remaining S/N ratio values were used for statistical analyses. Homogeneity of inter-plate sample variances across the 8 plates was investigated per Levene’s test using S/N ratio values (Levene 1960).
Cut point factor determination
Floating cut point factors (CPFs) for parametric and non-parametric screening were determined using the S/N ratio values. A parametric method was used to calculate robust estimates of the mean and standard deviation (SD) of all S/N ratio values. The parametric 1% error rate floating CPF was then determined by multiplying the SD value by the 99th quartile of the t-distribution (with degrees of freedom equal to the number of S/N ratio values minus 1) and adding the product to the mean of S/N ratio values. The non-parametric 1% error rate CPF was determined by calculating the empirical 99th percentile of S/N ratio values.
False-negative error rate
The false-negative error rate, defined as the probability of observing an S/N ratio less than the CPF in a known positive sample, was calculated based on the mean and SD of all LPC S/N ratio values and a t-distribution with degrees of freedom equal to the number of ratio values minus 1.
Full method validation was completed for the aspects of intra- and inter-assay precision, sensitivity, selectivity, drug tolerance, interference by TSR-022, hook effect, assay robustness, and stabilities.
Assay sensitivity was defined as the concentration of anti-dostarlimab NAbs spiked in pNHS with dostarlimab at 250 μg/mL followed by drug removal treatment, which consistently generated a signal above or equal to the applicable cut point. The overall sensitivity was equal to the average concentration of all plates + t 0.05, z (one side) × SD. Multiple levels of NAb PCs were prepared by spiking desired NAb concentrations that span the cut point into pNHS with dostarlimab at 250 μg/mL. The sensitivity samples underwent the drug removal treatment prior to analysis. Six runs were performed by 2 analysts over 3 separate days.
Intra-assay precision was evaluated by running 6 independent validation samples for NCs, LPCs (533.6 ng/mL), and HPCs (2000 ng/mL) on a single plate. The inter-assay precision was measured using the PCs and NCs in all accepted validation runs.
To determine if the assay demonstrated a hook effect, an ultrahigh concentration (20,000 ng/mL) of NAb was prepared in pNHS. Serial 2-fold dilutions of this sample in pNHS generated samples at 10,000, 5000, 2500, 1250, 625, 312.5, 156.25, 78.13, and 39.06 ng/mL, which were evaluated as replicates.
Ten individual cancer serum samples, 5 2% hemolyzed normal serum samples and 5 lipemic normal serum samples (450 μg/dL) containing dostarlimab at 250 μg/mL (a) unspiked and (b) spiked with anti-dostarlimab NAb at the LPC level (533.6 ng/mL), underwent drug removal treatment and were tested.
Interference in the detection of LPC was evaluated by using the isotype IgG4 antibody TSR-022, which is an anti-TIM3 antibody. The results were considered acceptable if the TSR-022–spiked LPC sample values were within their respective ranges, which were established during this validation. Drug interference was tested using 3 sets of LPC and NC (a) unspiked and (b) spiked with TSR-022 at 1350, 450, and 150 μg/mL. The drug removal treatment was applied to drug tolerance samples prior to analysis.
The robustness of the assay was determined by varying the incubation time as described in Table S1. Plates were run concurrently and analyzed on the same day by a single analyst.
To assess the stability of the NAb, samples of HPC, LPC, and NC were stored in 3 different conditions: 4 h at ambient temperature, 24 h at 2–8 °C, or subject to 6 freeze-thaw cycles.
The assay suitability criteria were established using the data from 15 of the 19 validation runs (robustness was not used to establish criteria).
A competitive ligand-binding assay was designed to detect NAbs against dostarlimab. In brief, biotinylated human PD-1 captured on a streptavidin-coated plate binds with SULFO-TAG–labeled human PD-L1 to generate the ECL assay signal. Additionally, the intensity of the ECL signal is proportional to the binding amount of PD-1 and PD-L1 complex. When the constant amount of dostarlimab is added, it competitively binds to PD-1, which results in the inhibition of the assay signal from PD-1 and PD-L1 complex. In the presence of anti-dostarlimab NAb, dostarlimab can be neutralized and unable to bind with PD-1, which triggers the increase of assay signal corresponding to a NAb-positive result (Fig. 1).
In the study, samples from patients treated with dostarlimab may contain excess drug, potentially resulting in assay interference. Thus, the excess dostarlimab must be removed before the assay via the drug removal procedure (Fig. 2; see “Materials and methods” for the drug removal procedure). The drug removal efficiency was monitored through an enzyme-linked immunoassay (ELISA) assay with the validated range of 32.0–814 ng/mL (data on file). This process confirmed that the processed samples had below quantification limit results in the ELISA assay, thus demonstrating that at least 250 μg/mL of the drug could be removed during the drug removal process. The drug removal step allows the assay to gain drug tolerance of at least 250 μg/mL, which matches the level required for the 3-tier bridging ADA assay (data on file).
Sources of variation
Figure 3 illustrates the variation in NC ECL values listed across assay runs and plates. No NC values had a high percent coefficient of variation (%CV > 20%), and no values were identified as statistical outliers, leaving all 32 NC values in the final analysis. The Levene test for homogeneity of variances for runs and analysts showed that the variances of NC ECL values among runs and analysts were equal (Levene test, P = 0.1073).
S/N ratio values
Figure 4 provides scatter diagrams with box plots and variances of the serum S/N ratio values versus the assay run and analyst from 60 cancer sera. The boxplot data indicated no statistically significant difference between runs and analysts. The Levene test of the S/N ratio values showed that the variances were equal among runs and analysts (Levene test, P = 0.1006).
NAb assay cut point and CPF
The NAb assay cut point (ACP) was defined as the level of assay response above or below which a sample is potentially positive or negative for the presence of NAbs. To evaluate the ACP and CPF, 60 individual human serum samples underwent the drug removal process and were screened for ACP factor determination along with control samples over 8 runs using 1 plate per run. Samples with %CV > 20% were excluded from the data set and not included in the ACP calculations. Overall, 92.5% of data points were included in the calculation, and the overall mean of the rECL values (mean sample ECL value divided by mean plate NC ECL value) was determined. The distribution of the rECL values was found to be normal (the Shapiro-Wilk test, P = 0.3069). The skewness coefficient was within acceptable limits (P = 0.1955), suggesting the parametric estimate could be used. Figure 5 provides a scatter plot of the plate-specific ECL values from the human serum samples versus the ECL values of the NC on the corresponding plates. The linear relationship between sample ECL and NC ECL is shown with a slope of 0.92 (P < 0.0001), supporting the application of a floating CPF for screening test samples for the presence of dostarlimab NAbs.
After excluding the statistical outliers by box plot analysis (high limit = Q3 + 1.5 × [Q3 − Q1] and low limit = Q1 − 1.5 × [Q3 − Q1], where Q3 is the 75th percentile and Q1 is the 25th percentile), the ACP was calculated by parametric analysis using the following equations:
The CPF was found to be 1.18; thus, the plate-specific cut points were calculated using the following equation:
False-negative error rate
An estimate of the LPC false-negative error rate was determined based on the distribution of S/N ratio values, where S was the ECL for the LPC and N was the mean of the ECL of the NC on the same plate. The probability of an S/N ratio less than the parametric CPF of 1.18 was determined by calculating the probability of a t-distribution with 15 degrees of freedom having a t-value less than ([NAb CPF − mean of S/N ratio values]/SD of S/N ratio values). The false-negative error rate was computed to be < 0.1 % with all the LPC (500 ng/mL) S/N ratio values being above the 1.18 factor. The false-negative rate is a regulatory concern. With a defined CPF, the likelihood for samples with NAb concentrations as low as 500 ng/mL to be determined as negative is minimal.
Sensitivity (Table 1)
Assay sensitivity was determined to be 476.5 ng/mL using the formula
Intra-assay precision was evaluated by running 6 independent validation samples for each level (NC, LPC, and HPC) on a single plate. The %CV of the intra-assay precision was 7.7, 7.5, and 8.1 for the HPC, LPC (500 ng/mL), and NC respectively (Table 2). The %CV of the inter-assay precision was 19.0, 23.9, 14.8, and 8.0 for the HPC, LPC-1 (500 ng/mL), LPC-2 (533.6 ng/mL), and NC, respectively (Table 3). Therefore, the intra-assay precision and inter-assay precision results met the specified criteria of %CV ≤ 20% and %CV ≤ 25%, respectively (Gupta et al. 2011).
Results in Table S2 show that the ECL signal of the NAb sample with the highest concentration (20,000 ng/mL) was above the cut point. Even though the signal levels of NAb concentrations higher than 1250 ng/mL were slightly decreased, a large hook effect was not observed at higher NAb concentrations. Therefore, a positive signal would still be detected if the sample contained up to 20,000 ng/mL anti-dostarlimab NAbs.
Overall, 95% of the spiked samples (human cancer serum, hemolyzed normal serum, and lipemic normal serum) had mean ECL values greater than the plate-specific cut point, and 90% of the unspiked samples had mean ECL values less than the plate-specific cut point (Table 4). Thus, the selectivity of the method met the acceptance criteria with all 3 serum types: cancer serum, hemolyzed normal serum, and lipemic normal serum.
As shown in Table 5, all TSR-022–spiked NC samples had ECL values below the cut point, and TSR-022–spiked LPC samples had ECL values above the cut point. Therefore, as long as the drug removal step is performed, even high levels of TSR-022 (up to 1350 μg/mL) do not interfere with the signal for the LPC or NC.
All robustness runs met the acceptance criteria (Table S3). Therefore, the assay was deemed robust with an incubation time ranging from 30 to 90 minutes per step: plate blocking, dostarlimab-NAb incubation, or sample incubation in MSD plate (Table S1).
To assess the stability of NAbs, samples of HPC, LPC, and NC were stored at 3 different conditions: 4 h at ambient temperature, 24 h at 2–8 °C, or subject to 6 freeze-thaw cycles. All ECL signals of samples assessed for stability were within the established acceptance criteria (Table S4). Therefore, NAbs passed all the stability tests performed.
System suitability criteria
The assay suitability criteria were used as part of the run acceptance criteria to determine whether a run should be rejected or accepted during validation stability testing and study sample analysis. The following system suitability criteria were obtained:
NC range: rECL 0.76–1.24
LPC-1 range: rECL 1.82–11.01
LPC-2 range: rECL 4.62–12.00
HPC range: rECL 5.11–18.36
NC < ACP < LPC < HPC
Analysis of all the validation runs showed that all QCs and NCs were within the acceptable range.
Initially, a cell-based assay was chosen to determine if it would meet the acceptance criteria to function as the NAb assay (Cong et al. 2015). This cell-based bioluminescent reporter assay was developed to quantify the NAb to the therapeutic mAbs for either anti–PD-1 or anti–PD-L1 that block the PD-1/PD-L1 interaction. PD-1 effector cells that express a nuclear factor of activated T cells (NFAT)-luciferase reporter and a human PD-1 receptor were engineered from Jurkat T cells (Cong et al. 2015). When the engineered Jurkat T cells were cocultured with antigen-presenting cells that expressed T cell receptor (TCR) activator and PD-L1, activation of the NFAT pathway through TCR activator/TCR complex interaction would normally occur, leading to bioluminescence (Cong et al. 2015). However, engagement of PD-1 and PD-L1 on the cells would block the NFAT pathway and bioluminescence. Both anti–PD-1 and anti–PD-L1 mAbs were able to block the PD-1/PD-L1 interaction, resulting in the recovery of NFAT pathway signaling and bioluminescence (Cong et al. 2015). This assay, which can be used as a potency assay for anti–PD-1 drugs, was our starting point for NAb assay development. However, the assay was labor intensive, had low tolerance for serum, and lacked sensitivity (data on file), which did not allow the cell-based reporter assay to move forward as a validated anti-dostarlimab NAb assay.
The current trend for choosing a NAb assay format includes using the therapeutic MOA as the driving selection criterion and, in addition, relies on both assay performance characteristics and the risk of immunogenicity to the patient (Wu et al. 2016). When considering the MOA of the drug, both drug-target interaction and the structural characteristics need to be examined. Dostarlimab is an antagonistic mAb that directly blocks the function of the extracellular domains of PD-1, which are responsible for the interaction with PD-L1 and signal transduction to the intra-cellular domains. Since dostarlimab blocks the specific PD-1/PD-L1 interaction by binding to the PD-1 receptor, instead of binding at another site to exert its effect, a non–cell-based NAb assay is adequate for NAb detection (Wu et al. 2016). Two other anti–PD-1 mAbs, nivolumab and pembrolizumab, also directly block the interaction of PD-1 with its ligands. Currently, non–cell-based assays are used for the detection of NAbs to nivolumab and pembrolizumab (van Vugt et al. 2019; Enrico et al. 2020).
Assay performance and clinical relevance
A cell-based assay was evaluated before the white paper on assay format assessment was published (Wu et al. 2016). Extensive optimization of the cell-based assay, including PD-L1 cell plating density, recovery of PD-1/PD-L1 co-culture or induction time, human serum concentration, cell culture plate type, luciferase substrate volume and reaction time, and plate reader setting, were completed to improve the assay sensitivity. Under optimal assay conditions, the sensitivity in the presence of 0.4 μg/mL of the drug was determined to be 12 μg/mL by screening 50 lots of human cancer serum. Since this was far from the USA Food and Drug Administration recommended assay sensitivity of 100 ng/mL, it was concluded that this assay was highly insensitive and was not serviceable for NAb detection. Furthermore, unlike most other cell-based assays, which require only 1 type of cell line, the PD-1/PD-L1 blockade bioassay required culturing, maintenance, and preparation of 2 independent cell lines, followed by co-culturing in an appropriate ratio to mimic PD-1/PD-L1 function in vivo. Undoubtedly, this would potentially create more uncertainty leading to less sensitive and less reproducible results.
The drug tolerance of this NAb assay was at least 250 μg/mL with the implementation of the drug removal process. This level of tolerance is based on the exposure level observed from the recommended therapeutic dose (4 doses of 500 mg Q3W followed by 1000 mg Q6W afterwards) established in the GARNET study. The exposure evaluation was done at cycles 1, 4, 5, 8, and 12, and only pre-dose samples were used for the immunogenicity evaluation. During the treatment process, the highest observed concentration, which was confirmed ADA-positive through 3-tier ADA assays, was lower than 250 μg/mL. The drug tolerance of this assay allows all samples to be evaluated with the low inconclusive rate. In the NAb assay validation, the cut point was determined using 60 individual human serum samples with the CPF of 1.18. The selection of the 60 cancer sera was balanced with respect to age, sex, and cancer types. This CPF can be applied to different indications without bias. The GARNET study includes multiple patient populations, and in its NAb evaluation, it is unclear whether this pre-study cut point is suitable for the population being studied (ClinicalTrials.gov 2016). Statistical determination of validation and in-study immunogenicity cut points were performed by the same statistician at Frontage Laboratory (Exton, PA) using the same procedures. An in-study cut point was determined statistically. S/N ratio responses (also called rECL) from 40 individual pre-dose baseline serum samples from the GARNET study that were negative in the NAb assay were used for the cut point analysis. Out of the 40 S/N ratios, no outliers were identified, and all values were included in cut point determination. The normality of the 40 S/N ratio responses was evaluated using the Shapiro-Wilk test, and the test gave a P value = 0.0754, which is more than 0.01 (1%), indicating that the data set of 40 S/N ratio values was considered to be normally distributed.
The in-study parametric CPF for the NAb was calculated as 1.35 at a 1% false-positive error rate. In the original NAb sample analysis based on the method validation CPF of 1.18 at the 1% false-positive error rate for the GARNET study, 64 of 135 confirmed ADA-positive samples were determined to be NAb positive. Upon retrospective application of the higher in-study cut point, 18 of the 64 samples switched from NAb positive to NAb negative. Based on the 3-tier ADA assays, 13 patients had treatment-emergent ADAs. Of these 13 patients, 7 patients were confirmed as NAb positive and the other 6 were NAb negative using both the validation cut point and the in-study cut point. Use of the higher in-study NAb cut point did not change the number of patients with treatment-emergent ADAs who were positive for NAbs, and thus would have no effect on the overall interpretation of the immunogenicity findings for this study using the tiered approach of 3-tier ADA assays and this NAb assay. Furthermore, method sensitivity and drug tolerance should not be greatly impacted by the lot of serum samples used for the establishment of cut point(s). The 60 lots of serum samples were selected to balance for cancer type, age, and sex. In addition, only 40 pre-dose samples from the study were used to calculate the in-study cut point, which was not optimal. Method sensitivity and drug tolerance should be evaluated by spiking in the pooled pre-dose samples of the study. This was not required here since the validation cut point can be further used due to limited impact as demonstrated in the above analysis results. With the limited positive ADA data in the GARNET study, no clinically relevant impact was observed from PK, safety, or efficacy, which is consistent with the observation that in currently approved anti–PD-1 mAbs, the presence of ADAs and NAbs does not correlate with an impact on pharmacokinetics, pharmacodynamics, safety, or efficacy (Davda et al. 2019; Enrico et al. 2020).
Because the clinical implications of ADAs and NAbs against dostarlimab remain unclear, both ADAs and NAbs to dostarlimab should be accurately detected using an established assay, such as that described here (Enrico et al. 2020). As has been demonstrated with other anti–PD-1 mAbs, a validated non–cell-based competitive ligand-binding assay is appropriate for detecting NAbs against dostarlimab with suitable precision, sensitivity, and selectivity (Enrico et al. 2020; Center for Drug Evaluation and Research 2017). Detection of ADAs, especially NAbs, is extremely important for the evaluation of efficacy and safety of biologic therapeutics. NAbs act by neutralizing biologic therapeutics; therefore, their presence may diminish drug efficacy. To this end, we have established an assay that can detect NAbs against dostarlimab, a humanized anti–PD-1 antibody. We have determined the CPF for the detection of neutralizing anti-dostarlimab antibodies in human serum at a 1% false-positive rate. The assay’s precision, sensitivity, hook effect, selectivity, robustness, and drug interference were tested and found to be acceptable. The performance of the assay was independent of runs and analysts. With the system’s suitability, stability, and drug tolerance, which covers the drug concentration range for the therapeutic dose established, this assay has been used to evaluate NAbs to support the clinical trials that help guide the development of dostarlimab.
Availability of data and materials
GSK makes available anonymized individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to www.clinicalstudydatarequest.com. To access data for other types of GSK sponsored research, for study documents without patient-level data, and for clinical studies not listed, please submit an inquiry via the website.
Assay cut point
Cut point factors
Coefficient of variation
Mechanism of action
Meso Scale Diagnostics
Nuclear factor of activated T cells
Programmed death 1
Programmed death ligand 1
Pooled normal human serum
- S/N :
Signal to noise
T cell receptor
Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY et al (2019) Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 145(6):1613–1623
Andre T, Berton D, Curigliano G, Ellard S, Perez JMT, Arkenau HT et al (2021) Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancer: results from the GARNET study. J Clin Oncol 39(suppl 3):abstr 9
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 37(4):311–319
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, PACIFIC Investigators et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929
Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R et al (2017) Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study. J Clin Oncol 35(15 suppl):4528
Bloem K, Hernández-Breijo B, Martínez-Feito A, Rispens T (2017) Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context. Ther Drug Monit 39(4):327–332
Center for Drug Evaluation and Research (2017) Approval package for: application number 125514Orig1s014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125514Orig1s014.pdf. Accessed 4 Feb 2021.
ClinicalTrials.gov (2016) Study of TSR-042, an anti-programmed cell death-1 receptor (PD-1) monoclonal antibody, in participants with advanced solid tumors (GARNET): NCT02715284. https://clinicaltrials.gov/ct2/show/NCT02715284. Accessed 6 May 2020. https://clinicaltrials.gov/ct2/show/NCT02715284?term=02715284&draw=2&rank=1
Cong M, Cheng Z, Karassina N, Grailer J, Hartnett J, Cosby N, Fan F et al (2015) Advertorial: novel bioassay to assess PD-1/PD-L1 therapeutic antibodies in development for immunotherapy. Genet Eng News 35(10) https://www.genengnews.com/magazine/247/advertorial-novel-bioassay-to-assess-pd-1-pd-l1-therapeutic-antibodies-in-development-for-immunotherapy/. Accessed 14 Aug 2020
Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J et al (2019) Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer 7:105
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389(10088):2492–2502
Enrico D, Paci A, Chaput N, Karamouza E, Besse B (2020) Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin Cancer Res 26(4):787–792
European Medicines Agency (2021) Jemperli. https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli. Accessed 24 May 2020
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, POPLAR Study Group et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 387(10030):1837–1846
Garcês S, Demengeot J (2018) The immunogenicity of biologic therapies. Curr Probl Dermatol 53:37–48
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8
Gunn GR, Sealey DCF, Jamali F, Meibohm B, Ghosh S, Shankar G (2016) From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin Exp Immunol 184(2):137–146
Gupta S, Devanarayan V, Finco D, Gunn GR III, Kirshner S, Richards S et al (2011) Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 55(5):878–888
Jolicoeur P, Tacey RL (2012) Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis. 4(24):2959–2970
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10):1374–1385
Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A et al (2019) Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 125(22):4019–4032
Krishna M, Nadler S (2016) Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol 7:21
Levene H (1960) Robust tests for the equality of variances. In: Oaklin I (ed) Contributions to probability and statistics. Stanford University Press, Palo Alto, pp 278–292
Liao K, Sikkema D, Wang C, Chen K, DeWall S, Lee TN (2012) Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody. J Immunol Methods 375(1–2):258–263
Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M et al (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1–16
Oaknin A, Ellard SL, Leath C III, Moreno V, Kristeleit R, Guo W et al (2018) Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients (pts) with recurrent or advanced MSI-H endometrial cancer. Ann Oncol 29(suppl8):viii334
Pineda C, Hernandez GC, Jacobs IA, Alvarez DF, Carini C (2016) Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 30:195–206
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 384(9948):1109–1117
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965
Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D et al (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48(5):1267–1281
Shapiro SS, Wilk MB (1965) Analysis of variance test for normality (complete samples). Biometrika. 52:591–611
US Food and Drug Administration. (2021a) FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer. Accessed 24 May 2021.
US Food and Drug Administration. (2021b) FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors. Accessed 16 Sept 2021.
van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC et al (2019) Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer 7(1):212
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384
Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R et al (2016) Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J 18(6):1335–1350
Wu Y, Akhgar A, Li J, Yu B, Chen C, Lee N et al (2018) Selection of a ligand-binding neutralizing antibody assay for benralizumab: comparison with an antibody-dependent cell-mediated cytotoxicity (ADCC) cell-based assay. AAPS. 20(3):49
Medical writing and editorial assistance, funded by GlaxoSmithKline (Waltham, Massachusetts) and coordinated by Hasan Jamal, MSc, of GlaxoSmithKline, were provided by Shannon Morgan-Pelosi, PhD, and Jennifer Robertson, PhD, of Ashfield MedComms, an Ashfield Health company (Middletown, CT, USA).
Funding for this study was provided by GlaxoSmithKline (NCT02715284). Trademarks are owned by or licensed to the GSK group of companies.
Xiaolong Tom Zhang has nothing to disclose. Hong Chen has nothing to disclose. Weiping Shao has nothing to disclose. Zhongping John Lin has nothing to disclose. Murad Melhem is an employee of GlaxoSmithKline. Sharon Lu is an employee of Scholar Rock and was affiliated with GlaxoSmithKline at the time of the study analyses.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Weiping Shao was employed by Frontage Laboratories when the research was conducted.
About this article
Cite this article
Zhang, X.T., Chen, H., Shao, W. et al. A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open 7, 8 (2021). https://doi.org/10.1186/s41120-021-00039-w
- Endometrial cancer
- Neutralizing antibodies
- Competitive ligand-binding assay